Atrion Corporation (NASDAQ:ATRI) Chairman Emile A. Battat sold 1,408 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $652.91, for a total value of $919,297.28. Following the completion of the transaction, the chairman now owns 148,881 shares in the company, valued at approximately $97,205,893.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Atrion Corporation (NASDAQ ATRI) traded up 1.90% during trading on Thursday, reaching $670.50. The company had a trading volume of 11,291 shares. Atrion Corporation has a 52-week low of $393.95 and a 52-week high of $691.95. The company has a market capitalization of $1.24 billion, a PE ratio of 37.57 and a beta of 0.91. The company has a 50 day moving average price of $629.25 and a 200 day moving average price of $557.05.

Atrion Corporation (NASDAQ:ATRI) last released its earnings results on Tuesday, August 8th. The medical instruments supplier reported $5.40 EPS for the quarter. The firm had revenue of $36.16 million for the quarter. Atrion Corporation had a return on equity of 18.67% and a net margin of 22.75%. On average, equities analysts forecast that Atrion Corporation will post $9.90 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 15th will be paid a $1.20 dividend. This is a boost from Atrion Corporation’s previous quarterly dividend of $1.05. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $4.80 annualized dividend and a yield of 0.72%. Atrion Corporation’s payout ratio is presently 23.52%.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/09/07/insider-selling-atrion-corporation-atri-chairman-sells-1408-shares-of-stock.html.

Separately, BidaskClub upgraded Atrion Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 29th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATRI. Schwab Charles Investment Management Inc. lifted its stake in Atrion Corporation by 0.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 6,183 shares of the medical instruments supplier’s stock valued at $3,978,000 after acquiring an additional 19 shares in the last quarter. Outfitter Advisors LTD. bought a new stake in Atrion Corporation in the 2nd quarter valued at approximately $257,000. Bank of New York Mellon Corp lifted its stake in Atrion Corporation by 0.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 10,258 shares of the medical instruments supplier’s stock valued at $6,600,000 after acquiring an additional 76 shares in the last quarter. Legal & General Group Plc lifted its stake in Atrion Corporation by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 336 shares of the medical instruments supplier’s stock valued at $216,000 after acquiring an additional 14 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its stake in Atrion Corporation by 4,800.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 196 shares of the medical instruments supplier’s stock valued at $126,000 after acquiring an additional 192 shares in the last quarter. Hedge funds and other institutional investors own 59.72% of the company’s stock.

Atrion Corporation Company Profile

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Insider Buying and Selling by Quarter for Atrion Corporation (NASDAQ:ATRI)

Receive News & Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.